The article reports on the approval by the U.S. Food and Drug Administration (FDA) of tezepelumab-ekko, marketed as Tezpire, biologic drug as treatment of all types of severe asthma. The drug was developed by Amgen and AstraZeneca. The drug is the first asthma treatment targeting the thymic stromal lymphopoietin.